Peptris Technologies: Revolutionizing AI-Led Drug Discovery in 2026

Company Overview

Peptris Technologies was founded in 2019 in Bengaluru by Narayanan Venkatasubramanian, Shridhar Narayanan, Anand Budni, and Amit Mahajan. The company operates in the AI-led preclinical drug discovery sector, aiming to revolutionize the traditional drug development process.

Mission and Technology

Peptris Technologies' mission is to expedite drug discovery by leveraging AI to predict the success and failure of drug candidates early in the development process. The platform generates novel molecular structures and predicts properties such as toxicity and stability, aiming to narrow down the vast chemical space to a manageable number of promising candidates.

The company also focuses on repurposing existing compounds and reviving failed ones for new indications, leveraging existing safety data to shorten the drug development timeline.

Funding and Investors

In February 2026, Peptris Technologies raised ₹70 crore (approximately $7.7 million) in a Series A funding round co-led by IAN Alpha Fund and Speciale Invest, with participation from Tenacity Ventures and BYT Ventures. This follows an earlier round of about $1 million led by Speciale Invest in December 2023.

Lead Asset and Therapeutic Areas

Peptris' lead asset, PEPR-124, is a repurposed candidate licensed to Revio Therapeutics for the development of treatments for Duchenne muscular dystrophy, a rare genetic muscle-wasting disorder. PEPR-124 is described as Phase 2-ready and mutation-agnostic, meaning it would not depend on specific genetic faults in patients.

The company targets therapeutic areas including rare diseases, inflammation, oncology, and women's health, with a particular focus on areas that have historically received less research funding.

Future Plans

The funds raised will be used to deepen the technology, expand the drug pipeline, push programs towards clinical readiness, and build partnerships in North America and Europe. The company aims to strengthen its scientific and technology teams to continue its mission of revolutionizing drug discovery.

FAQs

What is Peptris Technologies' main focus?

Peptris Technologies focuses on AI-led preclinical drug discovery to reduce the time and cost of developing new drugs.

Who are Peptris Technologies' investors?

Peptris Technologies' investors include IAN Alpha Fund, Speciale Invest, Tenacity Ventures, and BYT Ventures.

What is PEPR-124?

PEPR-124 is Peptris Technologies' lead asset, a repurposed candidate licensed to Revio Therapeutics for treating Duchenne muscular dystrophy.

Conclusion

Peptris Technologies is at the forefront of AI-led drug discovery, aiming to transform the drug development landscape by predicting failures early and repurposing existing compounds. With significant funding and a strong team, the company is well-positioned to achieve its mission and make a significant impact in the pharmaceutical industry.

Call-to-Action

Discover more about the future of drug discovery at blogy.in. Join us in exploring the innovations that are shaping the pharmaceutical industry in 2026 and beyond.